Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Myfortic (mycophenolic acid) 180 mg and 360 mg delayed-release tablet

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2009

 

Summary View

 

WARNINGS

Pure Red Cell Aplasia
  • Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil (MMF) in combination with other immunosuppressive agents.  MMF is metabolized to mycophenolic acid (MPA), the active ingredient in Myfortic and the active form of the drug...

ADVERSE REACTIONS 

Postmarketing Experience
  • Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressive agents.

MEDICATION GUIDE

What are the possible side effects of Myfortic?

  • Myfortic can cause serious side effects...

What is the most important information I should know about Myfortic?

  • Stomach and intestinal bleeding can happen in people who take Myfortic. Bleeding can be severe and you may have to be hospitalized for treatment...
  • ...Your healthcare provider will do blood tests before you start taking Myfortic and during treatment with Myfortic to check your blood cell counts...

 

-
-